J. Huraux, Traité de virologie médicale, 2003.

M. Permanyer, E. Ballana, and J. A. Este, Endocytosis of HIV: anything goes, Trends in Microbiology, vol.18, issue.12, pp.543-51, 2010.
DOI : 10.1016/j.tim.2010.09.003

S. G. Sarafianos, Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and Inhibition, Journal of Molecular Biology, vol.385, issue.3, pp.693-713, 2009.
DOI : 10.1016/j.jmb.2008.10.071

J. Karn and T. Tat, Tackling tat, Journal of Molecular Biology, vol.293, issue.2, pp.235-54, 1999.
DOI : 10.1006/jmbi.1999.3060

D. Gheysen, Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells, Cell, vol.59, issue.1, pp.103-115, 1989.
DOI : 10.1016/0092-8674(89)90873-8

J. Martin-serrano and S. J. Neil, Host factors involved in retroviral budding and release, Nature Reviews Microbiology, vol.24, issue.7, pp.519-550, 2011.
DOI : 10.1038/nrmicro2596

F. Simon, Identification of a new human immunodeficiency virus type 1 distinct from group M and group O, Nature Medicine, vol.10, issue.9, pp.1032-1039, 1998.
DOI : 10.1038/381661a0

J. C. Plantier, A new human immunodeficiency virus derived from gorillas, Nature Medicine, vol.24, issue.8, pp.871-873, 2009.
DOI : 10.1038/nm.2016

L. Buonaguro, M. L. Tornesello, and F. M. Buonaguro, Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications, Journal of Virology, vol.81, issue.19, pp.81-10209, 2007.
DOI : 10.1128/JVI.00872-07

V. Supervie and N. J. , The hidden HIV epidemic : what do mathematical models tell us ? The case of France, Conférence de l'International AIDS Society, 2012.

P. Yéni, Prise en charge médicale des personnes infectées par le VIH. 2010. 16. HAS, Dépistage de l’infection par le VIH en France : Stratégies et dispositif de dépistage, p.44, 2009.

K. C. Sigaloff, HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review, The Lancet Infectious Diseases, vol.11, issue.10, pp.11-769, 2011.
DOI : 10.1016/S1473-3099(11)70141-4

A. Vigano, Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV

C. Riva, Transmitted virus with substitutions at position 215 and risk of virological failure in antiretroviral naive patients starting highly active antiretroviral therapy. XI International HIV drug resistance workshop : basic principles and clinical implications, pp.2-5, 2002.

E. Lanier, Effect of baseline 215D/C/S « revertant » mutations on virological response to lamivudine /zidovudine-containing regimens and emergence of 215Y upon virological failure. XI International HIV drug resistance workshop : basic principles and clinical implications, pp.2-5, 2002.

. Garcia-lerma, Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons, Proceedings of the National Academy of Sciences, vol.98, issue.24, pp.13907-13912, 2001.
DOI : 10.1073/pnas.241300698

C. Chappey, Evolution of amino acid 215 in HIV-1 reverse transcriptase in response to intermittent drug selection. XII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2003.

D. Costagliola, Presence of thymidine –associated mutations and response to d4T, abacavir and ddi in the control arm of the Narval ANRS 088 trial, th Conference on Retroviruses and opportunistic Infections. 4-8 february, 2001.

V. Calvez, Impact of stavudine phenotype and thymidine analogs mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial, Antiviral Therapy, vol.7, issue.3, pp.211-218, 2002.

J. García-lerma, H. Macinnes, D. Bennett, P. Reid, S. Nidtha et al., A Novel Genetic Pathway of Human Immunodeficiency Virus Type 1 Resistance to Stavudine Mediated by the K65R Mutation, Journal of Virology, vol.77, issue.10, pp.5685-93, 2003.
DOI : 10.1128/JVI.77.10.5685-5693.2003

F. Brun-vézinet, Clinically relevant interpretation of genotype for resistance to abacavir, AIDS, vol.17, issue.12, pp.1795-802, 2003.
DOI : 10.1097/00002030-200308150-00008

C. Stone, M. Ait-khaled, C. Craig, P. Griffin, and M. Tisdale, Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine, Antimicrobial Agents and Chemotherapy, vol.48, issue.4, pp.1413-1418, 2004.
DOI : 10.1128/AAC.48.4.1413-1415.2004

M. Miller, Multivariate analyses of antiviral response to tenofovir DF therapy in antiretroviral–experienced patients. XI International HIV drug resistance workshop : basic principles and clinical implications, pp.2-5, 2002.

N. Margot, B. Lu, A. Cheng, and M. Miller, Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903*, HIV Medicine, vol.35, issue.7, pp.442-50, 2006.
DOI : 10.1097/00002030-200401230-00012

. Parikh, K65R : a multi-nucleoside resistance mutation of a low but increasing frequency. XII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2003.

B. Masquelier, Genotypic and pharmacological determinants of the virological response to tenofovir in nucleoside reverse transcriptase inhibitorexperienced patients, Antivir Ther, vol.9, issue.3, pp.315-338, 2004.

J. Izopet, Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine, Journal of Medical Virology, vol.36, issue.4, pp.507-511, 1999.
DOI : 10.1002/(SICI)1096-9071(199912)59:4<507::AID-JMV14>3.0.CO;2-C

I. Pellegrin, Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy, AIDS, vol.13, issue.13, pp.1705-1709, 1999.
DOI : 10.1097/00002030-199909100-00014

G. Mulamba, Pre-steady state kinetic analysis of the incorporation of FTC 5’-monophosphate and 3TC 5’-monophosphate by mutants HIV-1 RTs K65R, K65R/Q151M and Q151M. 16 th International Conference on Antiviral Research, 2003.

A. Marcelin, Clinically Relevant Genotype Interpretation of Resistance to Didanosine, Antimicrobial Agents and Chemotherapy, vol.49, issue.5, pp.1739-1783, 2005.
DOI : 10.1128/AAC.49.5.1739-1744.2005

S. Capdepont, An additive/substractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients, Journal of Clinical Virology, vol.36, issue.1, pp.36-42, 2006.
DOI : 10.1016/j.jcv.2006.01.008

L. Assoumou, F. Brun-vézinet, A. Cozzi-lepri, D. Kuritzkes, A. Phillips et al., Standardization and Clinical Relevance of HIV Drug Resistance Testing Project of the Forum for Collaborative HIV Research.Initiatives for Developing and Comparing Genotype Interpretation Systems: External Validation of Existing Systems for Didanosine against Virological Response, J Infect Dis, 2008.

J. Waters, TAMs in HIV-1 RT associated with reduced response to tenofovir DF in antiretroviral-experienced patients, 13 th Conference on Retroviruses and opportunistic Infections. 5-8 february, p.633, 2006.

R. Kagan, T. Lee, L. Ross, R. Lloyd, . Jr et al., Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase, Antiviral Research, vol.75, issue.3, pp.210-218, 2007.
DOI : 10.1016/j.antiviral.2007.03.006

R. Kagan, Adefovir HIV-1 RT mutation K70E in the age of tenofovir. XIV International HIV Drug Resistance Workshop: basic principles and clinical implications, 2005.

N. Sluis-cremer, C. Sheen, S. Zelina, P. Torres, U. Parikh et al., Molecular Mechanism by Which the K70E Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Nucleoside Reverse Transcriptase Inhibitors, Antimicrobial Agents and Chemotherapy, vol.51, issue.1, pp.48-53, 2007.
DOI : 10.1128/AAC.00683-06

V. Miller, HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy, AIDS, vol.14, issue.2, pp.163-171, 2000.
DOI : 10.1097/00002030-200001280-00012

G. Moyle, Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.38, issue.4, pp.417-442, 2005.
DOI : 10.1097/01.qai.0000147521.34369.c9

D. Irlbeck, Treatment-emergent mutations for previously naïve HIV-infected adults failing ZDV+3TC+EFV and ABC+3TC+EFV (CNA30024). 11 th Conference on Retroviruses and Opportunistic Infections, 2004.

A. Rodriguez-french, The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy???Naive HIV-1-Infected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.35, issue.1, pp.22-32, 2004.
DOI : 10.1097/00126334-200401010-00003

J. Gathe and . Jr, SOLO, AIDS, vol.18, issue.11, pp.1529-1566, 2004.
DOI : 10.1097/01.aids.0000131332.30548.92

. Wirden, Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients, Antimicrobial Agents and Chemotherapy, vol.50, issue.7, pp.2553-2559, 2006.
DOI : 10.1128/AAC.00092-06

J. García-lerma, A Novel Genetic Pathway of Human Immunodeficiency Virus Type 1 Resistance to Stavudine Mediated by the K65R Mutation, Journal of Virology, vol.77, issue.10, 2003.
DOI : 10.1128/JVI.77.10.5685-5693.2003

S. Sungkanuparph, Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine, Journal of Clinical Virology, vol.41, issue.4, pp.310-313, 2008.
DOI : 10.1016/j.jcv.2007.12.015

D. Coutsinos, The K65R mutation subtype B and C HIV-1: rates of development and the implications of template-specific dislocation mutagenesis, Antiviral Therapy, vol.15, issue.2, p.13, 2010.

M. Wirden, Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients, AIDS, vol.23, issue.1, pp.95-104, 2009.
DOI : 10.1097/QAD.0b013e328319bc91

P. Harrigan, T. Mo, B. Wynhoven, J. Hirsch, Z. Brumme et al., Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors, AIDS, vol.19, issue.6, pp.549-54, 2005.
DOI : 10.1097/01.aids.0000163930.68907.37

B. Brenner, A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors, AIDS, vol.17, issue.1, pp.1-5, 2003.
DOI : 10.1097/00002030-200301030-00001

A. Deshpande, Resistance Mutations in Subtype C HIV Type 1 Isolates from Indian Patients of Mumbai Receiving NRTIs Plus NNRTIs and Experiencing a Treatment Failure: Resistance to AR, AIDS Research and Human Retroviruses, vol.23, issue.2, pp.335-375, 2007.
DOI : 10.1089/aid.2006.0183

J. Vingerhoets, Impact of baseline NNRTI mutations on the virological response to TMC125 in the Phase III clinical trials DUET-1 and DUET-2. XVI International HIV drug resistance workshop : basic principles and clinical implications, pp.12-16, 2007.

A. Marcelin, Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients, Antimicrobial Agents and Chemotherapy, vol.54, issue.1, pp.72-79, 2010.
DOI : 10.1128/AAC.01051-09

J. Vingerhoets, Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies, AIDS, vol.24, issue.4, pp.503-517, 2010.
DOI : 10.1097/QAD.0b013e32833677ac

J. Vingerhoets, Impact of transmitted drug resistance (TDR) on virological response to initial combination antiretroviral therapy (cART), Antiviral Therapy, vol.15, issue.2, p.125, 2010.

A. El, In vitro selection of novel etravirine-associated resistance mutations in B and non-B HIV-1 subtypes, Antiviral Therapy, vol.15, issue.2, p.134, 2010.

H. Azijn, TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1, Antimicrobial Agents and Chemotherapy, vol.54, issue.2
DOI : 10.1128/AAC.00986-09

A. Marcelin, Mutations selected in patients displaying treatment failure under an etravirine-containing regimen, Antiviral Therapy, vol.10, pp.3851-1886, 2011.

A. Maïga, Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naive Patients Infected with Non-B HIV-1 Subtypes, Antimicrobial Agents and Chemotherapy, vol.54, issue.2, pp.728-761, 2010.
DOI : 10.1128/AAC.01335-09

E. Asahchop, Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes, Antimicrobial Agents and Chemotherapy, vol.55, issue.2, pp.600-607, 2011.
DOI : 10.1128/AAC.01192-10

J. Eron, Characterization of the resistance profile of TMC278: 48-week analysis of the Phase III studies ECHO and THRIVE

M. Haddad, Impact of HIV-1 reverse transcriptase E138 mutations selected on rilpivirine drug susceptibility, Antiviral Therapy, vol.16, issue.1, p.18, 2011.

B. Masquelier, K. Assoumou, D. Descamps, L. Bocket, J. Cottalorda et al., Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir, Journal of Antimicrobial Chemotherapy, vol.61, issue.6, pp.1362-1370, 2008.
DOI : 10.1093/jac/dkn127

A. Marcelin, I. Cohen-codar, M. King, P. Colson, E. Guillevic et al., Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients, Antimicrobial Agents and Chemotherapy, vol.49, issue.5, pp.1720-1726, 2005.
DOI : 10.1128/AAC.49.5.1720-1726.2005

A. Maillard, J. Chapplain, O. Tribut, D. Bentué-ferrer, P. Tattevin et al., The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir???ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients, Journal of Clinical Virology, vol.38, issue.2, pp.131-139, 2007.
DOI : 10.1016/j.jcv.2006.11.011

URL : https://hal.archives-ouvertes.fr/hal-00690759

B. Masquelier, Human Immunodeficiency Virus Type 1 Genotypic and Pharmacokinetic Determinants of the Virological Response to Lopinavir-Ritonavir-Containing Therapy in Protease Inhibitor-Experienced Patients, Antimicrobial Agents and Chemotherapy, vol.46, issue.9, pp.2926-2932, 2002.
DOI : 10.1128/AAC.46.9.2926-2932.2002

R. Colonno, Identification of I50L as the Signature Atazanavir (ATV)???Resistance Mutation in Treatment???Naive HIV???1???Infected Patients Receiving ATV???Containing Regimens, The Journal of Infectious Diseases, vol.189, issue.10, pp.1802-1812, 2004.
DOI : 10.1086/386291

S. Vora, Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients, AIDS, vol.20, issue.1, pp.35-40, 2006.
DOI : 10.1097/01.aids.0000196179.11293.fc

H. Mo, N. Parkin, K. Stewart, L. Lu, T. Dekhtyar et al., Identification and Structural Characterization of I84C and I84A Mutations That Are Associated with High-Level Resistance to Human Immunodeficiency Virus Protease Inhibitors and Impair Viral Replication, Antimicrobial Agents and Chemotherapy, vol.51, issue.2, pp.732-737, 2007.
DOI : 10.1128/AAC.00690-06

A. Marcelin, P. Flandre, C. De-mendoza, B. Roquebert, G. Peytavin et al., Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients, Antivir Ther, vol.12, issue.2, pp.247-52, 2007.

A. Marcelin, Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients, Antimicrobial Agents and Chemotherapy, vol.52, issue.9, 2008.
DOI : 10.1128/AAC.00133-08

R. Camacho, Different substitutions under selective pressure at protease codon 82 in HIV-1 subtype G compared to subtype B infected individuals including a novel I82M resistance mutation. XIV International HIV Drug Resistance Workshop: basic principles and clinical implications, pp.7-11, 2005.

A. Marcelin, External Validation of Atazanavir/Ritonavir Genotypic Score in HIV-1 Protease Inhibitor-Experienced Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.PAP, issue.1, pp.127-135, 2006.
DOI : 10.1097/01.qai.0000219776.27798.e7

A. Brutus, The Neat Study: Virologic response in subjects receiving GW433908 (908) BID by viral load/CD4 cell Counts at study entry, XV International AIDS Conference, 2004.

A. Cohort, Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients, Antimicrob Agents Chemother, vol.51, issue.4, pp.1473-80, 2007.

J. Friend, Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen, AIDS, vol.18, issue.14, pp.1965-1971, 2004.
DOI : 10.1097/00002030-200409240-00016

C. De-mendoza, Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance, AIDS, vol.20, issue.7, pp.1071-1075, 2006.
DOI : 10.1097/01.aids.0000222084.44411.cc

S. De-meyer, T. Vangeneugden, B. Van-baelen, E. De-paepe, H. Van-marck et al., Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials, AIDS Research and Human Retroviruses, vol.24, issue.3, pp.379-88, 2008.
DOI : 10.1089/aid.2007.0173

N. Nijhuis, A novel genetic pathway involving L76V and M46I leading to lopinavir/r resistance. XVI International HIV drug resistance workshop : basic principles and clinical implications, pp.12-16, 2007.

C. Delaugerre, Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy, Antimicrobial Agents and Chemotherapy, vol.53, issue.7, pp.2934-2943, 2009.
DOI : 10.1128/AAC.01643-08

A. Marcelin, Genotypic Resistance Analysis of the Virological Response to Fosamprenavir-Ritonavir in Protease Inhibitor-Experienced Patients in CONTEXT and TRIAD Clinical Trials, Antimicrobial Agents and Chemotherapy, vol.52, issue.12, pp.4251-4258, 2008.
DOI : 10.1128/AAC.00514-08

A. Hill, Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial, HIV Medicine, vol.10, issue.10, 2009.
DOI : 10.1111/j.1468-1293.2009.00734.x

D. Giambenedetto and S. , A rigorous statistical learning method for the estimation and validation of weighted drug susceptibility scores applied to in vivo virological outcome prediction in atazanavir/ritonavir-containing HAART. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2008.

R. Bethell, No effect of subtype on susceptibility and virological response to TPV/r for treatment experienced patients. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2008.

D. Descamps, Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients, Journal of Antimicrobial Chemotherapy, vol.63, issue.3, pp.585-92, 2009.
DOI : 10.1093/jac/dkn544

D. Meyer and S. , Influence of Baseline Protease Inhibitor Resistance on the Efficacy of Darunavir/Ritonavir or Lopinavir/Ritonavir in the TITAN Trial, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.49, issue.5, pp.563-567, 2008.
DOI : 10.1097/QAI.0b013e318183ac9c

D. Meyer and S. , Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2008.

D. Meyer and S. , Confirmation of the negative impact of protease mutations I47V, I54M, T74P and I84V and the positive impact of protease mutation V82A on virological response to darunavir/ritonavir. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.9-13, 2009.

P. Sista, Subgroup analysis of baseline susceptibility and early virological response to enfuvirtide in the combined TORO studies. XII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2003.

M. Mink, Impact of HIV-1 gp41 amino acid substitutions (position 36-45) on susceptibility to T20 (enfuvirtide) in vitro ; analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3. XI International HIV drug resistance workshop : basic principles and clinical implications, pp.2-5, 2002.

M. Greenberg, Enfuvirtide (T-20) and T-1249 resistance : observations from phase II clinical trials of enfuvirtide in combination with oral antiretrovirals and a phase I/II dose-ranging monotherapy trial of T-1249. XI International HIV drug resistance workshop : basic principles and clinical implications, pp.2-5, 2002.

M. Greenberg, Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks, 10 th Conference on Retroviruses and Opportunistic Infections, 2003.

B. Chakraborty, Replicative fitness of HIV-1 strains with reduced susceptibility to protease-, reverse transcriptase-and entry (enfuvirtide)-inhibitors. XIII International HIV drug resistance workshop : basic principles and clinical implications, pp.8-12, 2004.

S. Walmsley, Development of a new genotypic resistance assay involving the entire gp41 sequence for evaluating resistance to enfuvirtide. XIII International HIV drug resistance workshop : basic principles and clinical implications, pp.8-12, 2004.

T. Melby, Evolution of enfurvitide resistance in longitudinal samples obtained after continued enfuvirtide dosing post-virological failure. XIV International HIV Drug Resistance Workshop: basic principles and clinical implications, 2005.

D. Cooper, Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection, New England Journal of Medicine, vol.359, issue.4, pp.355-65, 2008.
DOI : 10.1056/NEJMoa0708978

I. Malet, Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro, Antimicrobial Agents and Chemotherapy, vol.52, issue.4, 2008.
DOI : 10.1128/AAC.01228-07

H. Hatano, Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.54, issue.4, pp.389-93, 2010.
DOI : 10.1097/QAI.0b013e3181c42ea4

D. Silva and D. , HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens, Journal of Antimicrobial Chemotherapy, vol.65, issue.6
DOI : 10.1093/jac/dkq099

URL : https://hal.archives-ouvertes.fr/hal-00594696

F. Ceccherini-silberstein, Virological response and resistance in multi-experienced patients treated by raltegravir. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2008.

J. Waters, Evolution of resistance to the HIV integrase inhibitor (INI) elvitegravir can involve genotypic switching among primary INI resistance patterns. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.9-13, 2009.

A. Geretti, Prevalence and patterns of raltegravir resistance in treated patients in Europe, Antiviral Therapy, vol.15, issue.2, p.62, 2010.

S. Fransen, Comparison of Raltegravir Susceptible and Resistant Viruses Define the Contribution of Secondary Mutations to Reductions in Raltegravir Susceptibility, 17 th Conference on Retroviruses and Opportunistic Infection, 2010.

W. Huang, Identification of alternative amino acid substitutions at HIV-1 integrase codon 143 that confer reduced susceptibility to raltegravir, 18th Conference on Retroviruses and Opportunistic Infections, 2011.

M. Kobayashi, In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, Antimicrobial Agents and Chemotherapy, vol.55, issue.2, 2011.
DOI : 10.1128/AAC.01209-10

F. Damond, In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase, Antivir Ther, vol.10, issue.7, pp.861-866, 2005.

D. Desbois, B. Roquebert, and G. Peytavin, In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors, Antimicrobial Agents and Chemotherapy, vol.52, issue.4, pp.1545-1553, 2008.
DOI : 10.1128/AAC.01284-07

URL : https://hal.archives-ouvertes.fr/inserm-00263591

E. Witvrouw, Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis, Antivir Ther, vol.9, issue.1, pp.57-65, 2004.

N. Parkin, Antiretroviral drug resistance in non-subtype B, HIV-2 and SIV, Antivir Ther, vol.9, issue.1, pp.3-12, 2004.

B. Roquebert, Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen, AIDS, vol.22, issue.15, pp.2045-2051, 2008.
DOI : 10.1097/QAD.0b013e32830f4c7d

N. Garrett, Raltegravir treatment response in an HIV-2 infected patient: a case report, AIDS, vol.22, issue.9, pp.1091-1098, 2008.
DOI : 10.1097/QAD.0b013e3282f9b165

C. Charpentier, Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir, Antimicrobial Agents and Chemotherapy, vol.55, issue.3, pp.1293-1295, 2011.
DOI : 10.1128/AAC.00942-10